HOUSTON, May 13, 2020 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced that updated clinical data from an investigator-sponsored
Phase 1/2 trial led by Baylor College of
Medicine were selected for presentation during a poster
session at the upcoming American Society of Clinical Oncology
(ASCO) Annual Meeting. ASCO 2020 will be held virtually from
Friday, May 29 through Sunday, May 31, 2020. The data will be presented
by lead investigator, Brandon G.
Smaglo, M.D., FACP.
Presentation Details
Title: "A phase I trial targeting advanced or
metastatic pancreatic cancer using a combination of standard
chemotherapy and adoptively transferred nonengineered, multiantigen
specific T cells in the first-line setting (TACTOPS)"
Authors: Smaglo BG, et al.
Session Type: Poster Session
Session Title: Gastrointestinal
Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract: 4622
Poster: 230
The presentation will be available on demand to ASCO registrants
beginning May 29, 2020 at
8:00 a.m. ET. The poster will be
available in the Investors section of the Company's website at
markertherapeutics.com.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology
company specializing in the development of next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications. Marker's cell therapy
technology is based on the selective expansion of non-engineered,
tumor-specific T cells that recognize tumor associated antigens
(i.e. tumor targets) and kill tumor cells expressing those targets.
This population of T cells is designed to attack multiple tumor
targets following infusion into patients and to activate the
patient's immune system to produce broad spectrum anti-tumor
activity. Because Marker does not genetically engineer its T cell
therapies, we believe that our product candidates will be easier
and less expensive to manufacture, with reduced toxicities,
compared to current engineered CAR-T and TCR-based approaches, and
may provide patients with meaningful clinical benefit. As a result,
Marker believes its portfolio of T cell therapies has a compelling
product profile, as compared to current gene-modified CAR-T and
TCR-based therapies.
To receive future press releases via email, please
visit: https://www.markertherapeutics.com/email-alerts
Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the
Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are "forward-looking statements." Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: our research, development and regulatory
activities and expectations relating to our non-engineered
multi-tumor antigen specific T cell therapies; the effectiveness of
these programs or the possible range of application and potential
curative effects and safety in the treatment of diseases; the
potential benefits of orphan drug designation; and the timing and
success of our clinical trials, as well as clinical trials
conducted by our collaborators. Forward-looking statements are by
their nature subject to risks, uncertainties and other factors
which could cause actual results to differ materially from those
stated in such statements. Such risks, uncertainties and factors
include, but are not limited to the risks set forth in the
Company's most recent Form 10-K, 10-Q and other SEC filings which
are available through EDGAR at www.sec.gov. The Company assumes no
obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-report-updated-results-from-phase-12-trial-with-multitaa-specific-t-cell-therapy-in-patients-with-pancreatic-adenocarcinoma-at-asco-2020-annual-meeting-301058683.html
SOURCE Marker Therapeutics, Inc.